ReleaseWire

In a groundbreaking move for the health and wellness industry in Australia, MyLife365.me is a comprehensive health-tracking solution for millions. This innovative app is set to transform how Australians approach their health, focusing on combating the rising concern of fatty liver disease, a condition affecting about one in every three Australian adults.

As an aesthetic doctor focused on skin treatments in Vancouver, Dr. Kamani offers advanced solutions proven by science. It's no secret that Vancouver climate combined with dry indoor air during winter can leave skin in a less-than-ideal shape. SkinVive™ is a new solution that offers intense hydration from inside out, for up to nine months with a single treatment. For more, go to https://rozkamani.com/get-nine-months-of-glow-from-one-hyaluronic-acid-treatment/

Global Market Direct's pharmaceuticals report, "Sanofi Pasteur SA - Product Pipeline Review - 2013" provides data on the Sanofi Pasteur SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Akron Molecules GmbH - Product Pipeline Review - 2013" provides data on the Akron Molecules GmbH's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Ventria Bioscience - Product Pipeline Review - 2013" provides data on the Ventria Bioscience's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Neurotec Pharma SL - Product Pipeline Review - 2013" provides data on the Neurotec Pharma SL's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Affectis Pharmaceuticals AG - Product Pipeline Review - 2013" provides data on the Affectis Pharmaceuticals AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Proacta, Inc. - Product Pipeline Review - 2013" provides data on the Proacta, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Relevare Pharmaceuticals Ltd. - Product Pipeline Review - 2013" provides data on the Relevare Pharmaceuticals Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "nLife Therapeutics, S.L. - Product Pipeline Review - 2013" provides data on the nLife Therapeutics, S.L.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS). Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Global Markets Direct's, 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Retinoblastoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinoblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinoblastoma. Retinoblastoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "XTL Biopharmaceuticals Ltd. - Product Pipeline Review - 2013" provides data on the XTL Biopharmaceuticals Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "M et P Pharma AG - Product Pipeline Review - 2013" provides data on the M et P Pharma AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Synthetic Biologics, Inc. - Product Pipeline Review - 2013" provides data on the Synthetic Biologics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "SCYNEXIS, Inc. - Product Pipeline Review - 2013" provides data on the SCYNEXIS, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Ambrx, Inc. - Product Pipeline Review - 2013" provides data on the Ambrx, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Stemedica Cell Technologies, Inc. - Product Pipeline Review - 2013" provides data on the Stemedica Cell Technologies, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Foresee Pharmaceuticals, LLC - Product Pipeline Review - 2013" provides data on the Foresee Pharmaceuticals, LLC's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency. Alpha- Antitrypsin Deficiency - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Global Market Direct's pharmaceuticals report, "AC Immune SA - Product Pipeline Review - 2013" provides data on the AC Immune SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "MediciNova, Inc. - Product Pipeline Review - 2013" provides data on the MediciNova, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Arterial Thrombosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Arterial Thrombosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arterial Thrombosis. Arterial Thrombosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.